API | setrobuvir

setrobuvir Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Setrobuvir was an experimental drug candidate for the treatment of hepatitis C that was discovered at Anadys Pharmaceuticals, which was acquired by Roche in 2011; Roche terminated development in July 2015. It was in Phase IIb clinical trials, used in combination with interferon and ribavirin, targeting hepatitis C patients with genotype 1. ^Wikipedia

Chemistry

SMILES: CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)[C@@H]3[C@H]4CC[C@H](C4)[C@@H]3N(Cc3ccc(F)cc3)C1=O)N2
InChIKey: DEKOYVOWOVJMPM-RLHIPHHXSA-N
Mol. Mass: 560.63
ALogP: 2.98 Partition coefficient
ChEMBL Molecule:
setrobuvir

More Chemistry

Pharmacology

Mechanisms of Action:
- Genome polyprotein (Hepatitis C virus genotype 1b (strain HC-J4) (HCV)) ^UniProt
- RNA-directed RNA polymerase (Hepatitis C virus) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

abt-072 | ana598 | ana-598 | ro5466731 | setrobuvir

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Healthy Volunteers (Phase 1)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 14
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue